**Medical Marijuana BHRS Position Statement**

* We do not support the use of “medical marijuana,” cannabinoids or any other compounds containing delta-9-tetrahydrocannabinol (THC), the main active chemical in marijuana, outside the FDA regulatory process to approve pharmaceutical products
	+ Lack of adequately powered, well controlled clinical trials. Further research needed to evaluate the therapeutic benefits of cannabinoids
	+ also concerns regarding purity, dosing and formulation (need to formulate safely as we do for any other medication)
* We do not support off-label use of dronabinol (Marinol®)
	+ Dronabinol is FDA approved for the use of appetite stimulation in AIDS patients and chemotherapy-induced nausea and vomiting
	+ It is not FDA approved for the treatment of other conditions such as pain, PTSD, Crohn's & Alzheimer's
* The available evidence suggests that
	+ long-term cannabis use among young people (15-25 years) can lead to social, behavioral, educational and mental problems
	+ recreational and therapeutic use of cannabinoids by young men may confer malignant potential to testicular germ cells
	+ chronic exposure to THC may accelerate the age-related loss of nerve cells
	+ Addiction
		- about 17% who start using marijuana during adolescence & 25-50% of daily users become addicted
		- 70-72% of 12-17 year olds enter drug treatment programs primarily because of marijuana addiction
	+ Marijuana can be very harmful to children and adolescent health and development
		- damaging effects on brain development, cognition, and social functioning
		- can impair memory and concentration, alter motor control, coordination & judgment
		- regular use is linked to a higher likelihood of drug dependence in adulthood
		- frequent cannabis use in teenage girls predicts later depression and anxiety, with daily users carrying the highest risk
* Some studies suggest marijuana may alleviate chemotherapy-induced vomiting, cachexia, spasticity associated with multiple sclerosis, and neuropathic pain; but, there is no significant evidence marijuana is superior to currently available FDA approved medications to treat these conditions
* We recognize cannabinoids may have potential as a therapy for certain conditions and some clients may benefit from cannabinoids, exceptions should be made for compassionate use in cliets with debilitating or life-limiting conditions (subject to review by medical chief/medical director) ?
* Currently, BHRS providers are not in a position to recommend the use of “medical marijuana” or refer clients to outpatient treatment clinics

References

1. Drug Facts. National Institute on Drug Abuse. [www.drugabuse.gov/drugs-abuse/marijuana. Published December 2012](http://www.drugabuse.gov/drugs-abuse/marijuana.%20Published%20December%202012).
2. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009 Oct 17;374(9698):1383-91
3. Lacson, John Charles A., et al. "Population‐based case‐control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk." *Cancer* 118.21 (2012): 5374-5383.
4. Meier, Madeline H., et al. "Persistent cannabis users show neuropsychological decline from childhood to midlife." *Proceedings of the National Academy of Sciences* 109.40 (2012): E2657-E2664.
5. Nistler C, Hodgson H, Nobrega FT, Hodgson CJ, Wheatley R, Solberg G. Marijuana and adolescents. Minn Med. 2006 Sept:49-51.
6. Patton, George C., et al. "Cannabis use and mental health in young people: cohort study." *Bmj* 325.7374 (2002): 1195-1198.
7. Silins, Edmund, et al. "Young adult sequelae of adolescent cannabis use: an integrative analysis." *The Lancet Psychiatry* 1.4 (2014): 286-293.
8. Wilkinson ST, and D’Souza DC. “Problems with the Medicalization of Marijuana” JAMA Vol. 311 No. 23 p. 2377 (June 18,, 2014).